Skip to main
AMPH
AMPH logo

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. is positioned for significant growth, with expectations to meet or surpass growth targets for 2025 and 2026, aligning its revenue generation and price-to-earnings (P/E) ratios closer to industry peers. The recent FDA approval of AMP-002 is a pivotal development that alleviates prior regulatory uncertainties and opens new potential revenue streams for the company. Additionally, the firm's focus on technically challenging pharmaceutical products and a strong market presence in the U.S., China, and France further supports a positive outlook on its financial performance.

Bears say

Amphastar Pharmaceuticals Inc. faces a negative outlook due to several fundamental issues, including dependence on the U.S. market, which poses risks should any regulatory changes or competitive pressures arise. The company's focus on technically challenging products does not eliminate the risks associated with rising manufacturing costs and potential supply chain disruptions, which may impact profitability. Additionally, the limited geographical diversification beyond the U.S., China, and France raises concerns about the firm’s overall revenue stability in light of potential market fluctuations.

Amphastar Pharma (AMPH) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Buy based on their latest research and market trends.

According to 5 analysts, Amphastar Pharma (AMPH) has a Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.